Tiankang (301263.SZ) subsidiary CKBA Cream for Vitiligo indications received Phase II clinical trial preliminary results and achieved expected goals.

date
04/08/2025
Zhitan Financial APP News, Tairon Holdings (301263.SZ) announced that recently, its controlling subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan") independently developed a type 1 innovative drug CKBA ointment for the treatment of vitiligo has completed the data collection and unblinding of the phase II clinical trial. The preliminary results indicate that CKBA ointment has shown positive efficacy and good safety in non-segmental vitiligo patients. The trial results are satisfactory, meeting the expected goals, and support the continuation of phase III confirmatory clinical trials. The related research data will also be submitted to the CDE for breakthrough therapy application and registration clinical communication in the near future.